Related Experiment Video
Updated: May 11, 2025

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
Evaluation of pregabalin-induced oedema using the adverse event spontaneous reporting database and the prescription
Hitoshi Ito1, Yoshitaka Hasegawa1, Mamoru Maeda1
1AIN Holdings Inc., Shibuya-ku, Tokyo 151-0053, Japan.
Objectives:
Pregabalin may reduce the quality of life due to oedema, which may lead to further adverse events if co-administered with diuretics. This study investigated the occurrence of oedema and loop diuretic prescriptions in Japanese patients treated with pregabalin, including the temporal characteristics of the onset and factors associated with oedema.
Methods:
Using the Japanese Adverse Drug Event Report database, we performed logistic regression analysis to calculate adjusted reporting odds ratios to assess the association between pregabalin and oedema, and time-of-onset analysis to identify the timing of oedema onset. Using the prescription claims database of the Japanese pharmacy group, we assessed the occurrence of loop diuretic prescriptions associated with pregabalin by calculating the adjusted sequence ratios in the prescription sequence symmetry analysis, and identified the associated factors in subgroup analyses.
Key Findings:
The adjusted reporting odds ratio was 6.89 (95% confidence interval: 5.96-7.91) for pregabalin, adjusted for age and sex as covariates. The median time to onset of oedema was 16.0 days (interquartile range: 6.0-42.0 days). The adjusted sequence ratio was 1.17 (95% confidence interval: 1.09-1.25), with subgroup analyses confirming a significant association at starting doses of 150 mg/day and more.
Conclusions:
This study suggests that oedema and loop diuretic prescriptions are associated with pregabalin use. Pregabalin-induced oedema was more common early in treatment and loop diuretics were more likely to be prescribed when the starting dose of pregabalin was 150 mg/day or more.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drugs for Treatment of Constipation-Predominant IBS
Non-Oral Extravascular Drug Absorption Routes
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more...

